# Value Based Insurance Design-Opportunities for Clinicians to Engage

March 24, 2011

Dr. Jeff Rideout - SVP and Chief Medical Officer, TriZetto



### Value-Based Insurance Design

VBID emerged from the observation that short-term cost savings resulting from increased cost sharing may decrease patient health and in certain circumstances increase aggregate health care cost



The system should provide incentives to patients and clinicians to encourage the use of high value services



## Key Takeaways From This Talk

**Value Purchasing is More Critical Than Ever** 

Consumer Health and Demand Can Managed Using Value Based Insurance Design ("Smart Benefits")

Physician Engagement is Critical to Value Based Strategies But Is Only In Its Infancy

Recent MLR Definitions Regarding Qualifying Medical Expenses Are Very Favorable for Value Based Solutions



## Agenda

### The Urgency of Value

Consumer Incentives- The "Demand" Side

Clinician Incentives – The "Supply" Side

Value-based strategies and health reform



### Returning Value to the Health Care Debate

# Healthcare cost growth isn't going away with the passage of reform

Health Care share of GDP made its biggest one-year jump ever in 2009, going from 16.2 to 17.3%




...and substantial underutilization of high value health care services persists



# Spending and Health Are Not Correlated

Life Expectancy in the G7 Countries vs. Predicted Life Expectancy based on Standard of Living and Expenditures on Health Care





### "Do No Harm" - Cost Containment Efforts Should NOT Produce Reductions in Quality of Care



Up to 60% of chronically ill patients have poor adherence to evidence-based treatment

Responsible for up to one-quarter of all hospital and nursing-home admissions

Costs from poor medication adherence estimated to exceed \$100 billion annually

Non-Adherence to Evidence-Based Services: already a cost and quality problem



Dunbar-Jacob, Journal of Clinical Epidemiology 54 (2001) S57-S60.



### Blunt Cost Control Can Make Things Worse

### Copays increased:

- from \$7.38 to \$14.38 for primary care
- from \$12.66 to \$22.05 for specialty care
- remained unchanged at \$8.33 and \$11.38 in controls

### ► In the year after increases:


- 19.8 fewer annual outpatient visits per 100 enrollees
- 2.2 additional hospital admissions per 100 enrollees



- Effects worse in low income and patients with chronic illness
- 5 year study of almost 900,000 Medicare enrollees in 36 states



# High Copays Also Reduce Adherence to Appropriate Medication Use



- When copays were doubled, patients took less medication in important classes. These reductions in medication levels were profound
- Reductions in medications supplied were also noted for:
  - NSAIDs 45%
  - Antihistamines 44%
  - Antiulcerants 33%
  - Antiasthmatics 32%
  - Antidepressants 26%
- For patients taking medications for asthma, diabetes, and gastric disorders, there was a 17% increase in annual ER visits and a 10% increase in hospital stays

**ER** = Emergency room

Goldman DP et al. JAMA, 2004; 291:2344-2350



### What to Do? Focus on Appropriateness of Care

# \$600-800 billion is spent on care that does nothing to improve our health\*

#### **Demand-Side**

Personal choices and behaviors drive excessive demand



#### **Supply-Side**

Existing model encourages excessive volume

#### **Administrative**

Inefficiencies in administrative transactions, communication, and information sharing



## Example of a Value-Based Insurance Design



### Person is a newly diagnosed diabetic

- Offered an incentive to either complete an online course on managing diabetes or to speak with a health coach
- When completed, receives reduced co-pays on diabetes drugs, supplies and diabetes-related office visits, labs



- Incented and enrolled in a diabetes DM program if indicated
- Ideally patient's physician is incented to provide EBM based care, appropriate referrals (e.g. DTC), education (informed decision making) and ongoing management support between office visits

## Agenda

### The Urgency of Value

**Consumer Incentives – The "Demand" Side** 

Clinician Incentives – The "Supply" Side

Value-based strategies and health reform



### Consumers Understand The Value of VBID

### Reasons for Enrolling In a Value Based Benefit Plan

	Consumers (867)
The financial benefits	87%
The health benefits	59%
It was the only type of plan offered by employer	1%
Some other reason	3%

2010 TriZetto survey research


Q10a Why would you be likely to enroll in this type of plan?



# ... and VBID Availability Will Likely Impact Consumer Choice

#### Consumers:


Will VBID encourage switching to a different insurance company?





### QuadMed VBID Results






#### **Quad/Med Program:**

- ▶ No patient costs for chronic care treatment for diabetes, asthma, hypertension
- Incorporated fitness and better health management
- Up to \$400 per employee for goal achievement



### City of Asheville VBID Results

Annual percentage of participants requiring ER visits or hospitalizations



#### **City of Asheville Asthma Program:**

- No patient costs for asthma medications
- Asthma education provided to participants



### CDHP vs. VBID- Better Together

### **CDHP**

- 8 million and growing at a rate of 34%/year
- Savings average \$900-1000/member per year vs.
   "low" CDHP employers
- Lower rate increases (3.5% vs. 6.1%)

#### but.....

 Poorer care and medication compliance for the chronically ill

### **VBID**

- Higher care and drug compliance
- Lower hospitalization and ER rates for chronically ill
- Cost savings demonstrated in specific settings

#### but....

 Higher initial utilization of services, so impact on premiums & ROI unclear



## Agenda

The Urgency of Value


Consumer Incentives – The "Demand" Side

Clinician Incentives – The "Supply" Side

Value-based strategies and health reform



# Plenty of Physician Engagement in Value Based Payment Schemes



# The Promise of PCMH & Lots of Expectations

#### **Classic PCMH Definition**

- Take personal responsibility and <u>accountability for the ongoing care</u> of patients;
- Be <u>accessible</u> to their patients on short notice for expanded hours and open scheduling;
- Be able to conduct consultations through <u>email and telephone</u>;
- Utilize the latest health information technology and <u>evidence-based</u> <u>medical approaches</u>, as well as maintain updated <u>electronic personal</u> <u>health records</u>;
- Conduct <u>regular check-ups</u> with patients to identify looming health crises, and <u>initiate treatment/prevention</u> measures before costly, lastminute emergency procedures are required;
- Advise patients on <u>preventative care</u> based on environmental and genetic risk factors they face;
- Help <u>patients make healthy</u> lifestyle decisions; and
- Coordinate care, when needed, making sure procedures are relevant, necessary and performed efficiently.

# And Lots of Government Support- PCMH in the Patient Protection and Affordable Care Act (PPACA)

- Medical Home is in 9 different sections of the PPACA
- Not new: Introduced in 1967 by American Academy of Pediatrics
- Puts Primary Care Physicians in central role of managing patients health
- Many other physician-based organizations have endorsed
- 'Cause Célèbre' on Capitol Hill

H. R. 3590

#### One Hundred Eleventh Congress of the United States of America

AT THE SECOND SESSION

Begun and held at the City of Washington on Tuesday, the fifth day of January, two thousand and ten

#### An Act

Entitled The Patient Protection and Affordable Care Act.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION L. SHORT TITLE: TABLE OF CONTENTS.

(a) SHORT TITLE.—This Act may be cited as the "Patient Protection and Affordable Care Act".

(b) TABLE OF CONTENTS.—The table of contents of this Act

(b) TABLE OF CONTENTS.—The table of contents follows:

Sec. 1. Short title; table of contents.

TITLE I—QUALITY, AFFORDABLE HEALTH CARE FOR ALL AMERICANS
Subtitle A—Innediate In provenents in Health Care Coverage for All Americans
Sec. 1001. Amendments to the Public Health Service Act.



## Some Fair Questions from Physicians

"Everybody is in favor of progress. It's the change they don't like."

Anonymous

- Demonstrate the benefits to me and my patients specifically
- How will this affect my workflow and revenue?
- What will it cost me to participate?
- Data and analytics whose data and can I trust it?





### Current PCMH State of the Art-Deloitte Brief


- 100 planned or established programs
  - Average number of physicians involve less than a few hundred
  - Largest over 8,000, but many less than 30
  - Few formal studies of effectiveness.
- Program designs are highly variable- 2010 Harvard study (Bitton, et al)
  - Study id'ed 26 programs encompassing 15,000 physicians in 4700 practices
  - Highly variable structural, financial and operational features
  - Models typically use a collaborative chronic care model or an external consultant-facilitated model
- Four key success themes- 2010 Harvard study (Fields, et al)
  - Dedicated care managers, expanded access, data driven analytic tools, new incentives; HIT is the essential front end investment
  - Savings typically several hundred dollars per patient
- National Demonstration Project from 2006-2008 concluded PCMH model is potentially effective but requires significant investment and operating competencies
- Health plans lead several of the most successful efforts



## Keys to Success: The Single Patient View

### ➤ What everyone should know:

- Which patients are high risk?
- Are patients compliant to evidence based guidelines?
- Are they motivated to maintain their health status?
- What interventions are most effective?
- Who is most likely to have a hospital or ER visit?
- Medication & Care History
- What is the patients evidence-based care plan?





### Value of Superior Analytics

# Example 1: Using Acute & Chronic Impact Index

**Disease Focus: Diabetes** 

Total Population: 925,407 members Diabetic Population: 50,847 members Savings Potential: \$62,643,504

High-Risk
Population
Risk Levels 4 & 5

14,250 Members Forecasted Cost: \$14,634 Prior Year Cost: \$14,527

Savings
Potential:
\$1,524,750

High Acute & Chronic Impact Population

13,872 Members Forecasted Cost: \$8,698 Prior Year Cost: \$5,089

Savings Potential: \$50,064,048

#### **Example 2:** Using Movers

Focus: High-Risk Members Forecasted with Upward Risk Movement

Total Population: 216,842 members

Top 2% High-Risk Members

4,362 Members
Forecasted Cost:
\$25,741
Prior Year Cost:
\$45,006

Savings Potential: -\$84,033,930 Movers with Forecasted Cost Increase >= 50%

498 Members Forecasted Cost: \$20,084

Prior Year Cost: \$8,832

Savings Potential: \$5,603,496



# Example: Physician Portal Home Page








# Example: My Patient List







### Example: Patient Profile








# Example: Patient Profile (Continued)

isk Navigator Provider			DMO Hospital Sys	tem -		04/01/2005 - 03/31/20	
ome My Patient List Disease Registry Di	aonosis Profile Utilization	Profile		AND THE RESERVE OF THE PERSON			
Maintenance Drug Compliance							
		Lact Fill	I Date	% Compliance		Next Fill Date	
Drug Name		Last Fill Date		% сопрнансе		Next Fill Date	
METOPROLOL TARTRATE		01/23/2006		66.4%		04/24/2006	
CLONIDINE HCL	NIDINE HCL		2006	66.4%		04/24/2006	
UROSEMIDE		01/23/2006		66.4%		04/24/2006	
CALCIUM ACETATE		01/23/	2006	66.4%		04/24/2006	
op <u>Patient Diagnosis</u> <u>Care History Maintenance</u> Laboratory Clinical Opportunities	Drugs Lab Opportunities Gu	ideline Compliance					
Lab Test Name	First Test - Abnormal?	First Test - Date	First Test - Result	Last Test - Abnormal?	Last Test - Date	Last Test - Result	
Guideline Compliance							
Guideline Group		Description					
Guidelille Group			Description			Compliant	
***************************************	Breast cancer sc	reening: Women 40-6	Paradia Marana			<b>Compliant</b> Yes	
***************************************	200000000000000000000000000000000000000	reening: Women 40-6 eening: Age 50 and o	9 years				
***************************************	200000000000000000000000000000000000000	eening: Age 50 and o	9 years			Yes	
reventive Care-Women	Colon cancer scr Tobacco avoidan	eening: Age 50 and o	9 years	tions		Yes NO	
Preventive Care-Women	Colon cancer scr Tobacco avoidan Influenza immuniz	eening: Age 50 and o	69 years Ilder e 5-64 with chronic condi	tions		Yes NO Yes	
Preventive Care-Women	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur	eening: Age 50 and o ice zation: Individuals ag zation: Individuals ag nization: Age >=65 or	69 years Ilder e 5-64 with chronic condi e 50 to 64 2-64 with chronic condit	ion		Yes NO Yes	
Preventive Care-Women	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur Plus Hypertension	eening: Age 50 and o ice zation: Individuals ag- zation: Individuals ag- nization: Age >=65 or n: ACE-I, ARB, beta-b	i9 years Ider e 5-64 with chronic condi e 50 to 64 2-64 with chronic condit olocker, diuretic or digoxin	ion		Yes NO Yes NO NO	
Preventive Care-Women	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur Plus Hypertension Plus Hypertension	eening: Age 50 and o ice zation: Individuals ago zation: Individuals ago nization: Age >=65 or n: ACE-I, ARB, beta-t n: echocardiogram, a	is years  Ider  e 5-64 with chronic condit e 50 to 64 2-64 with chronic condit blocker, diuretic or digoxin ge >= 18	ion		Yes NO Yes NO NO NO	
Preventive Care-Women Preventive Care	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur Plus Hypertension Plus Hypertension ACE-I, ARB or be	eening: Age 50 and o ice zation: Individuals ago zation: Individuals ago nization: Age >=65 or n: ACE-I, ARB, beta-t n: echocardiogram, a ta-blocker; Age >= 1	is years  Ider  e 5-64 with chronic condit e 50 to 64 2-64 with chronic condit plocker, diuretic or digoxin ge >= 18	ion		Yes NO Yes NO NO NO Yes	
Preventive Care-Women Preventive Care	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur Plus Hypertensior Plus Hypertensior ACE-I, ARB or be ACE-I, ARB, diure	eening: Age 50 and o oce zation: Individuals ago zation: Individuals ago nization: Age >=65 or n: ACE-I, ARB, beta-b n: echocardiogram, ago ta-blocker; Age >= 1	is years Ilder  e 5-64 with chronic condit e 50 to 64 2-64 with chronic condit plocker, diuretic or digoxin ge >= 18 8 digoxin; Age >=18	ion		Yes NO Yes NO NO NO Yes Yes Yes	
reventive Care-Women	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur Plus Hypertensior Plus Hypertensior ACE-I, ARB or be ACE-I, ARB, diure Plus Hypertensior	eening: Age 50 and of occepation: Individuals agration: Individuals agration: Age >=65 or at ACE-I, ARB, beta-ta-blocker; Age >= 1 etic, beta-blocker or at ACE-I, ARB or beta	is years  Ider  e 5-64 with chronic condit  e 50 to 64  2-64 with chronic condit  blocker, diuretic or digoxin  ge >= 18  8  digoxin; Age >=18  blocker; Age >=18	ion		Yes NO Yes NO NO NO Yes Yes Yes Yes	
Preventive Care-Women Preventive Care	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immur Plus Hypertensior Plus Hypertensior ACE-I, ARB or be ACE-I, ARB, diure Plus Hypertensior	eening: Age 50 and of occepation: Individuals agration: Individuals agration: Age >=65 or at ACE-I, ARB, beta-ta-blocker; Age >= 1 etic, beta-blocker or at ACE-I, ARB or beta	is years Ilder  e 5-64 with chronic condit e 50 to 64 2-64 with chronic condit plocker, diuretic or digoxin ge >= 18 8 digoxin; Age >=18	ion		Yes NO Yes NO NO NO Yes Yes Yes Yes Yes	
Preventive Care-Women Preventive Care	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immun Plus Hypertension Plus Hypertension ACE-I, ARB or be ACE-I, ARB, diure Plus Hypertension Diuretic plus seru Eye exam (retina	eening: Age 50 and of occepation: Individuals agration: Individuals agration: Age >=65 or occapation: AGE-I, ARB, beta-base echocardiogram, agrata-blocker; Age >= 1 etic, beta-blocker or occapation: ACE-I, ARB or beta on chemistry panel or of performed	is years  Ider  e 5-64 with chronic condit  e 50 to 64  2-64 with chronic condit  blocker, diuretic or digoxin  ge >= 18  8  digoxin; Age >=18  blocker; Age >=18	ion		Yes NO Yes NO NO NO Yes Yes Yes Yes Yes Yes	
Preventive Care-Women Preventive Care	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immun Plus Hypertension Plus Hypertension ACE-I, ARB or be ACE-I, ARB, diure Plus Hypertension Diuretic plus seru Eye exam (retina Hemoglobin A1c (	eening: Age 50 and of once seation: Individuals age seation: Individuals age seation: Age >=65 or seation: Age >=65 or seation: Age >= 1 s	is years  Ider  e 5-64 with chronic condit  e 50 to 64  2-64 with chronic condit  blocker, diuretic or digoxin  ge >= 18  8  digoxin; Age >=18  blocker; Age >=18	ion		Yes NO Yes NO NO NO Yes Yes Yes Yes Yes Yes Yes Yes	
Preventive Care-Women  Preventive Care  Heart Failure	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immun Plus Hypertension Plus Hypertension ACE-I, ARB or be ACE-I, ARB, diure Plus Hypertension Diuretic plus seru Eye exam (retina	eening: Age 50 and of once seation: Individuals age seation: Individuals age seation: Age >=65 or seation: Age >=65 or seation: Age >= 1 s	is years  Ider  e 5-64 with chronic condit  e 50 to 64  2-64 with chronic condit  blocker, diuretic or digoxin  ge >= 18  8  digoxin; Age >=18  blocker; Age >=18	ion		Yes NO Yes NO NO NO Yes	
Preventive Care-Women  Preventive Care  Heart Failure	Colon cancer scr Tobacco avoidan Influenza immuniz Influenza immuniz Pneumonia immun Plus Hypertension Plus Hypertension ACE-I, ARB or be ACE-I, ARB, diure Plus Hypertension Diuretic plus seru Eye exam (retina Hemoglobin A1c (	eening: Age 50 and of occe zation: Individuals ago zation: Individuals ago zation: Age >=65 or n: ACE-I, ARB, beta-b n: echocardiogram, ago ta-blocker; Age >= 1 etic, beta-blocker or of n: ACE-I, ARB or beta am chemistry panel or l) performed (HbA1c) testing y: ACE-I or ARB	is years  Ider  e 5-64 with chronic condit  e 50 to 64  2-64 with chronic condit  blocker, diuretic or digoxin  ge >= 18  8  digoxin; Age >=18  blocker; Age >=18	ion		Yes NO Yes NO NO NO Yes	






# Example: Disease Registry








## Example: Diagnosis Profile







## Example: Utilization Profile







# Reminder- There Are Lots of New Payment Options to Consider

- ► Patient Centered Medical Home and...
- Payment Bundling/episode of care payments (ACE)
- Traditional capitation/ "new" CMS global payment programs
- Accountable Care Organizations
- Next generation Pay for Performance
- Hospital performance scores
- Medicare re-admission, never event and avoidable condition payment rules
- New NAIC medical loss ratio (MLR) qualifying expenses



# Agenda

The Urgency of Value

Consumer Incentives – The "Demand" Side

Clinician Incentives – The "Supply" Side

Value-based strategies and health reform



### Healthcare Reform Affects Finances in 3 Waves

#### First Wave: 2010


 Integrate new costs into their economic models (Rescissions, dependent coverage, lifetime and annual limits)

#### **Second Wave: 2011-2013**

- Meet Medical Loss Ratio (MLR) requirements
- Begin transitioning to new exchange distribution model
- Massive shifts in business line profitability and enrollment

#### Third Wave: 2014

- Integrate \$8B in federal fees
- Required competency in consumer marketing





### The MLR Qualifying Funnel

### Recommendations from the NAIC to HHS Pursuant to the PPACA





STATE INSURANCE REGULATORS & NAIC

NAIC HOME | CIPR HOME | ABOUT THE N.

### Quality **Improvement** IN

- **Improved Health Outcomes**
- **Reducing Health Disparities**
- **Hospital Readmission Prevention**
- Improved Patient Safety & Medical **Error Reduction**
- Increase Wellness
- **Enhanced Use of Healthcare Data**



Objectively measured showing verifiable results and achievement - not designed primarily to contain costs



**Expense directed toward individual members** or specific segments of enrollees



Grounded in EBM, widely held clinical practice, government bodies, national quality organizations and/or accreditation bodies



- Network Management
- ► UM
- Claims processing
- ► ICD 10



### Qualifying QI Activities- A Deeper Look

- Improve Health Outcomes- Care and Disease Management, Coaching, Compliance support, PCMH, Reporting, Data Analytics
- Prevent Hospital Re-admission- Discharge planning, post discharge care, analytics, information sharing post discharge
- Improve Patient Safety and Reduce Medical Errors- error identification and prevention, infection control, analytics, data sharing
- Wellness and Health Promotion- wellness assessment, coaching and education, prevention, HIT associated with these activities
- HIT for Healthcare Quality Improvement





## "Column 1"- Improve Health Outcomes

- Effective Case management, Care coordination, and Chronic Disease Management, including:
  - Patient centered intervention such as:
    - Making/verifying appointments,
    - Medication and care compliance initiatives,
    - Arranging and managing transitions from one setting to another (such as hospital discharge to home or to a rehabilitation center), and
    - Reminding insured of physician appointment, lab tests or other appropriate contact with specific providers;





# "Column 1"- Improve Health Outcomes (cont)

- Effective Case management, Care coordination, and Chronic Disease Management, including:
  - Incorporating feedback from the insured to effectively monitor compliance;
  - Providing coaching to encourage compliance with evidence based medicine;
  - Activities to identify and encourage evidence based medicine;
  - Use of the medical homes model as defined for purposes of section 3602 of PPACA); and
  - Medication and care compliance initiatives, such as checking that the insured is following a medically effective prescribed regimen for dealing with the specific disease/condition and incorporating feedback from the insured in the management program to effectively monitor compliance;





### "Column 4"- Wellness and Health Promotion

Expenses for programs that provide wellness and health promotion activity (e.g., face-to-face, telephonic or web-based interactions or other forms of communication), including:

- Wellness assessment;
- Wellness/lifestyle coaching programs designed to achieve specific and measurable improvements;
- Coaching programs designed to educate individuals on clinically effective methods for dealing with a specific chronic disease or condition; and
- Coaching or education programs and health promotion activities designed to change member behavior (e.g., smoking, obesity); or
- Health information technology expenses to support these activities





# Key Takeaways From This Talk

**Value Purchasing is More Critical Than Ever** 

Consumer Health and Demand Can Managed Using Value Based Insurance Design ("Smart Benefits")

Physician Engagement is Critical to Value Based Strategies But Is Only In Its Infancy

Recent MLR Definitions Regarding Qualifying Medical Expenses Are Very Favorable for Value Based Solutions



### Case Studies of VBID



- Prescription drug / supply co-pays that incentivize high-value care
  - For asthma, diabetes, and heart disease drug classes: Pitney Bowes; Marriott Inc.; SEIU
  - Moving lower-value drugs to more costly tiers: Health Alliance Medical Plans, Inc.
  - Chronic conditions: Blue Cross Blue Shield North Carolina (3:1 returns)
- Drug and care service co-pays that incentivize high-value care
  - For diabetics: City of Asheville Project; University of Michigan "Focus on Diabetes" program; many others
  - Reduced co-pays and behavior rewards: Quad/Graphics
  - Zero co-pay for well-women, well-baby, diabetes drugs, colon cancer high-risk: Caterpillar
- Comparative effectiveness in consumer decision-making
  - Provider choice (tiers of providers based on comparative quality): Aetna Aexcel
  - Treatment choice (surgery): Colorado Springs School District 11; Hannaford Brothers
- Incentivizing health & wellness activities
  - Lower deductible for health and wellness activity participation: United Health Vital Measures Plan



### Recommended Reading on VBID



- Value-based Insurance Design Landscape Digest. Fendrick July 2009. Available at: http://www.sph.umich.edu/vbidcenter
- Value-Based Benefit Design: A Purchaser Guide. National Business Coalition on Health. Jan 2009. <a href="https://www.nbch.org">www.nbch.org</a>
- Health Plan Capabilities to Support Value-Based Benefit Design. National Business Coalition on Health October 2009. Available at: <a href="https://www.npcnow.org">www.npcnow.org</a>
- Aligning Incentives and Systems: Promoting Synergy Between Value-Based Insurance
   Design and the Patient Centered Medical Home. Fendrick, Sherman, Patient-Centered Primary
   Care Collaborative 2010. <a href="https://www.pcpcc.net">www.pcpcc.net</a>.
- Adding Value to PPO Services A White Paper on Value-Based Benefit Design. American Association of Preferred Provider Organizations 2009. Available at <a href="https://www.aappo.org">www.aappo.org</a>
- eValue8 National Business Coalition on Health's initiative for review of health plans. Available at: www.evalue8.com
- Pitney Bowes' VBID pilot results: Berger J. "Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy." Am J Manag Care 2007
- Value-based Insurance Design: Aligning Incentives to Bridge the Divide Between Quality
   Improvement and Cost Containment. Fendrick, Chernew Am J Manag Care 2006
- Value-based Insurance Design: A Clinically Sensitive Approach to Preserve Quality of Care and Contain Costs. Fendrick, Chernew.. Am J Manag Care 2006
- A Strategy for Health Care Reform Toward a Value-based System. Porter. NEJM 2009
- Value in Health Care: Preliminary Discussion Brief. IOM March 2009. Available at: ww.iom.edu
- vbidcenter.org research and additional case studies



# Thank you

#### Additional Resources:

- www.TriZetto.com
  - TriZetto Value-Based Benefits Solution a technology solution for health plans to design and administer value-based benefits and incentive programs
- www.TriZetto.com/vbidwp
  - Value-Based Insurance Design: A proactive approach to a healthier membership. New TriZetto research shows that payers, employers, providers, brokers and consumers are in agreement about the potential benefits of VBID and that demand is significant.



### TriZetto Constituent Survey Overview

### Methodology

Opinion Research conducted 1,761 interviews

Constituent Group	Number of Interviews	Sampling Error
Payers	157	8%
Brokers	200	7%
Employers	200	7%
Clinicians	203	7%
Consumers	1,001	3%

Reliability – 95% confidence level 60-day online survey, Oct. – Dec. 2009.

